H1-antihistamine use and head and neck cancer risk in type 2 diabetes mellitus
YI-NONG CHEN1,#, YING-LIN CHEN1,#, WAN-MING CHEN2,3, MINGCHIH CHEN2,3, BEN-CHANG SHIA2,3, JENQ-YUH KO1,4, SZU-YUAN WU2,3,5,6,7,8,9,10,11,*
Oncology Research, Vol.31, No.1, pp. 23-34, 2023, DOI:10.32604/or.2022.028449
- 01 March 2023
Abstract This study aimed to examine the association between the use of H1-antihistamines (AHs) and head and neck
cancer (HNC) risk in patients with type 2 diabetes mellitus (T2DM). Data from the National Health Insurance Research
Database of Taiwan were analyzed for the period from 2008 to 2018. A propensity-score-matched cohort of 54,384
patients each in the AH user and nonuser groups was created and analyzed using Kaplan-Meier method and Cox
proportional hazards regression. The results showed that the risk of HNC was significantly lower in AH users
(adjusted hazard ratio: 0.55, 95% CI: 0.48 to More >